Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Maximon is a Swiss longevity-focused company builder and investor that creates and supports science-based businesses in healthy aging and rejuvenation. Rather than operating as a traditional drug-development biotech, it incubates and finances companies across the longevity value chain, including consumer health, clinics, and digital health offerings. Its publicly described portfolio includes AVEA Life, a longevity supplements company, Ayun, a walk-in longevity clinic concept launched in Zurich, and Frieda Health, a digital health company focused on menopause support. Maximon positions itself as an ecosystem for founders by providing capital, venture-building support, scientific input, and access to a longevity-focused network. For biotech analysts, the key point is that Maximon is health-related and science-driven, but it is primarily a venture builder/platform business rather than a therapeutic pipeline company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Maximon.